Stocks Health care XTLB
NASDAQ · Health careXtl Biopharmaceuticals Ltd (XTLB)
Xtl Biopharmaceuticals Ltd reported revenue of $451K in fiscal 2024. It posted a net loss of $1M. In fiscal 2024 capital spending exceeded operating cash flow by $1.7M. At December 31, 2024 it held $371K in cash against $138K of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on June 30, 2026.
Key facts about Xtl Biopharmaceuticals Ltd
- Net worth
- Xtl Biopharmaceuticals Ltd has a market value (market cap) of $4.1M at the latest share price, and shareholders' equity of $5.4M on its balance sheet at December 31, 2024. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2024 revenue was $451K, with a net loss of $1M.
- Cash flow
- In fiscal 2024 operations used $1.6M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on June 30, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Xtl Biopharmaceuticals Ltd does
Xtl Biopharmaceuticals Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker XTLB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2024 | $451K | -$1M | -$0.00 | -$1.7M |
| 2024 | n/a | -$1.8M | -$0.00 | n/a |
| 2022 | n/a | -$1.3M | -$0.00 | n/a |
| 2021 | n/a | $435K | $0.00 | n/a |
| 2020 | n/a | -$3M | -$0.01 | -$851K |
| 2019 | n/a | -$763K | -$0.00 | -$910K |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where XTLB ranks in Health care
Latest SEC filings
What Xtl Biopharmaceuticals Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 5, 2026
- July 21, 2026
- June 30, 2026Annual report (foreign issuer) 20-F · period to December 31, 2025
- June 30, 2026
- June 29, 2026
- June 23, 2026
- May 22, 2026
- May 15, 2026
- May 7, 2026
- April 30, 2026Form NT 20-F filing NT 20-F
Insider trades
What the people running Xtl Biopharmaceuticals Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Questions about XTLB
What does Xtl Biopharmaceuticals Ltd do?
Xtl Biopharmaceuticals Ltd is a company in the Health care sector, listed on NASDAQ as XTLB. Its shares trade on NASDAQ under the ticker XTLB.
What is Xtl Biopharmaceuticals Ltd's net worth?
Xtl Biopharmaceuticals Ltd has a market value (market cap) of $4.1M at the latest share price, and shareholders' equity of $5.4M on its balance sheet at December 31, 2024. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Xtl Biopharmaceuticals Ltd profitable?
No. In fiscal 2024 it reported a net loss of $1M on revenue of $451K.
How much revenue does Xtl Biopharmaceuticals Ltd make?
In fiscal 2024 Xtl Biopharmaceuticals Ltd reported revenue of $451K.
When did Xtl Biopharmaceuticals Ltd last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on June 30, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from August 5, 2026.
Similar companies
Compare XTLB with
Follow XTLB
Get an email when Xtl Biopharmaceuticals Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Xtl Biopharmaceuticals Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.